SNDX Q1 2018 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+24.3% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$20M-5211.3% margin

Net Income

-$19M-5118.2% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-68.2%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$120M

Total Liabilities

$33M

Stockholders' Equity

$87M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$305,000	+24.3%
Gross Profit	$379,000	$305,000	+24.3%
Operating Income	-$20M	-$13M	-49.9%
Net Income	-$19M	-$13M	-49.5%